Under construction – not a live service
Sign in
Taking people in TürkiyeNo phase

Weight loss with GLP-1 medicines or sleeve gastrectomy in obesity

Compares GLP-1 medicines with stomach-reducing surgery in adults with obesity.

Key facts

Who runs it
Yuzuncu Yil University
Where
Van, TürkiyeSee the site
Trial code
Registry title
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
Status
Recruiting
People taking part
200 people, planned
Started
15 Sept 2026
Expected to end
15 Nov 2028
Type of study
Observational, 2 groups
Treatments tested
  • GLP-1 Receptor Agonist Therapy
  • Laparoscopic Sleeve Gastrectomy
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The study is looking for adults with obesity or overweight. Some start a GLP-1 medication as usual care. Others had a sleeve gastrectomy (stomach-reducing surgery) at the same center.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Obesity or overweight, treated either with a GLP-1 medication or with a first sleeve gastrectomy done between January 1, 2020 and January 1, 2026.
Earlier treatment
Cannot have had weight-loss (bariatric or metabolic) surgery before. The medication group starts a GLP-1 medication for weight management. The surgery group had a first laparoscopic sleeve gastrectomy for obesity.
Biomarker or test result
Height and body weight measurements from the start must be available.

Main reasons for not taking part

  • Weight-loss surgery before the main treatment, or repeat (revision) surgery
  • Active cancer or a serious illness that strongly affects body weight
  • Pregnant or breastfeeding
  • Uncontrolled hormone disease that can cause weight loss
  • Another weight-loss treatment or intensive program that could change the results

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • GLP-1 Receptor Agonist Cohort:
  • Age 18 years or older at treatment initiation
  • Initiation of a GLP-1 receptor agonist for obesity or overweight as part of routine clinical care
  • Available baseline height and body weight measurements
  • Willingness to attend at least one follow-up assessment
  • Ability to comply with the center's standard follow-up program
  • Provision of written informed consent; Laparoscopic Sleeve Gastrectomy Cohort:
  • Age 18 years or older at surgery
  • Primary laparoscopic sleeve gastrectomy for obesity performed at the study center between January 1, 2020, and January 1, 2026
  • Available preoperative height, body weight, and body mass index measurements
  • Available demographic and baseline clinical data
  • At least one documented postoperative body weight measurement. Availability of a 24-month weight measurement is preferred for the primary comparison

Who cannot take part

  • Bariatric or metabolic surgery before the index treatment
  • Revisional bariatric surgery as the index treatment
  • Concurrent use of another anti-obesity treatment that could substantially affect study outcomes
  • Medication prescribed but never administered; Laparoscopic Sleeve Gastrectomy Cohort:
  • Active malignancy or a serious systemic disease substantially affecting body weight
  • Uncontrolled endocrine disease that may cause weight loss
  • Both Cohorts:
  • Pregnancy or breastfeeding at the index treatment
  • Missing baseline height or body weight measurements
  • Recent participation in another intensive weight-loss program before the index treatment
  • Inability to reliably verify study data; GLP-1 Receptor Agonist Cohort:
  • Short-term GLP-1 receptor agonist use for an indication other than weight management
  • Sleeve gastrectomy performed concurrently with another bariatric procedure
  • Sleeve gastrectomy performed for an indication other than primary obesity treatment

Where in Türkiye

  • Yuzuncu Yıl UniversityVan, TürkiyeContact: Mahir CoşkunTaking people

About the trial

What the trial wants to find out

This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach.

Read full original descriptionShow less

Adults starting GLP-1 medications as part of their usual care will be followed for 24 months. Their results will be compared with existing medical records of adults who underwent sleeve gastrectomy at the same center. Treatment decisions will be made by patients and their treating clinicians as part of routine care, rather than assigned by the study.

The main outcome is the percentage of starting body weight lost at 24 months. The study will also assess weight changes at earlier visits, medication side effects, treatment continuation and reasons for stopping treatment, and changes in weight-related health conditions. The groups will be matched using baseline characteristics to make the comparison more balanced.

The 2 groups in the trial

  • GLP-1 Receptor Agonist Cohort

    Adults aged 18 years or older starting a GLP-1 receptor agonist, such as liraglutide or semaglutide, for weight management as part of routine clinical care. Participants will be followed prospectively for 24 months, with assessments at baseline and months 1, 3, 6, 12, and 24. Weight changes, medication use, treatment adherence, adverse events, and treatment discontinuation will be recorded. Medication selection and dosing will be determined by the treating clinician independently of study participation.

    Treatment: GLP-1 Receptor Agonist Therapy

  • Laparoscopic Sleeve Gastrectomy Cohort

    Adults who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026, and were aged 18 years or older at surgery. Existing medical records will be reviewed retrospectively for baseline characteristics, postoperative weight measurements through 24 months, and surgical complications. This cohort will be matched with the GLP-1 receptor agonist cohort using propensity scores based on pretreatment characteristics. Surgery was performed as part of routine clinical care independently of this study.

    Treatment: Laparoscopic Sleeve Gastrectomy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparison of Two-Year Weight-Loss Effectiveness of GLP-1 Receptor Agonists and Laparoscopic Sleeve Gastrectomy in the Treatment of Obesity: An Ambispective Propensity Score-Matched Cohort Study
Plain-language title
Weight loss with GLP-1 medicines or sleeve gastrectomy in obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
6 November 2026